Poseida thrives on new ways of thinking, fostering close collaborations, and holding ourselves to shared values – passion, innovation, and nimbleness.
Publications - Poseida Therapeutics
Explore our latest achievements in non-viral gene engineering including developments in our targeted CAR-T programs in oncology and gene editing programs in rare disease. Read the …
Poseida Therapeutics Highlights Positive Interim Phase 1 Results …
Dec 9, 2024 · Case study demonstrates reactivation of an autologous Poseida CAR-T therapy with a T-cell engager in patient with relapsed multiple myeloma, highlighting potential of T …
Poseida Therapeutics Announces FDA Clearance of …
SAN DIEGO, July 5, 2023 /PRNewswire/ — Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients …
Poseida Therapeutics Announces Leadership Appointments
SAN DIEGO, Oct. 13, 2021 /PRNewswire/ — Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform …
Optimizing Allogeneic Cell Therapy Manufacturing Processes …
•Poseida utilizes Cas-CLOVER™gene editing technology to knock out endogenous T cell receptor and MHC class I molecules to address GvHD and HvG Gene Editing to address
Poseida Therapeutics Hosts Second Annual Virtual R&D Day …
SAN DIEGO, Feb. 23, 2022 /PRNewswire/ — Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform …
Poseida Therapeutics Provides Updates and Financial Results …
Mar 7, 2024 · Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare …
Phase 1 Study of P-MUC1C-ALLO1 Allogeneic CAR-T Cells …
Poseida: P-MUC1C-ALLO1 •A high percentage of tumor samples tested positive for staining with scFv binder used by P-MUC1C-ALLO1 CAR. –~90% of breast and colon tumors were positive, …
Advanced gene editing with an enhanced site-specific nuclease …
Poseida Therapeutics, Inc. A Member of the Roche Group 9390 Towne Centre Drive Suite 200 San Diego, CA 92121 info@poseida.com
Careers - Poseida Therapeutics
Poseida thrives on new ways of thinking, fostering close collaborations, and holding ourselves to shared …
Publications - Poseida Therapeutics
Explore our latest achievements in non-viral gene engineering including developments in our targeted CAR-T programs in oncology and gene …
Poseida Therapeutics Highlights Positive Interim Ph…
Dec 9, 2024 · Case study demonstrates reactivation of an autologous Poseida CAR-T therapy with a T-cell engager in patient with relapsed multiple …
Poseida Therapeutics Announces FDA Clearance of I…
SAN DIEGO, July 5, 2023 /PRNewswire/ — Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new …
Poseida Therapeutics Announces Leadership Appoi…
SAN DIEGO, Oct. 13, 2021 /PRNewswire/ — Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing …
